News >

TAS-102 Plus Bevacizumab Is Potential New Option in Refractory mCRC

Jason Broderick
Published: Thursday, Mar 12, 2020

The addition of bevacizumab (Avastin) to TAS-102 (trifluridine/tipiracil; Lonsurf) reduced the risk of disease progression or death by 55% compared with TAS-102 alone in patients with chemorefractory metastatic colorectal cancer (mCRC), according to findings from an investigator-initiated, open-label, randomized phase II trial published in The Lancet Oncology

second-line treatment in patients who have progressed on a first-line bevacizumab-containing regimen.
Pfeiffer P, Yilmaz M, Möller S, et al. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21(3):412-420. doi: 10.1016/S1470-2045(19)30827-7.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication